Efficacy, Safety, and Pharmacokinetics of Coadministered Diethylcarbamazine, Albendazole, and Ivermectin for Treatment of Bancroftian Filariasis (2016)

Peer-Reviewed Study · Thomsen EK, Sanuku N, Baea M, Satofan S, Maki E, Lombore B, Schmidt MS, Siba PM, Weil GJ, Kazura JW, Fleckenstein LL, King CL · February 1, 2016

Thomsen EK et al., 2016-02-01: Randomized pilot trial in Papua New Guinea showing that single-dose triple therapy (DEC, albendazole and ivermectin) cleared Wuchereria bancrofti microfilariae in all 12 recipients at one year, against 1 of 12 with two drugs.

All 12 individuals who received 3 drugs were microfilaria negative 1 year after treatment, whereas 11 of 12 individuals in the 2-drug regimen were microfilaria positive.

Thomsen EK et al., 2016-02-01: Randomized pilot trial in Papua New Guinea showing that single-dose triple therapy (DEC, albendazole and ivermectin) cleared Wuchereria bancrofti microfilariae in all 12 recipients at one year, against 1 of 12 with two drugs. Randomized pilot study, N=24 adults (12 per arm), Papua New Guinea. Single oral dose of DEC 6 mg/kg + albendazole 400 mg, with or without ivermectin 200 micrograms/kg. Comparator: two-drug DEC+albendazole. Triple therapy produced >2-log microfilaria reduction at 36 and 168 hours versus about 1 log with two drugs; 6 participants followed to 2 years remained microfilaria negative. Funder and conflicts not carried in the PubMed record (paywalled full text); no disclosure statement indexed. This is the trial behind WHO's IDA recommendation, later scaled in larger studies. Study type: randomized trial.